CD274 and hepatocellular carcinoma: Furthermore, combining atezolizumab (an anti-PD-L1 antibody) with bevacizumab (an anti-VEGF antibody) has been shown to improve outcomes in patients with HCC.464 The rationale behind this combination is that by blocking PD-L1, the inhibition of T cell responses is abolished, whereas bevacizumab reduces tumor hypoxia and improves T cell infiltration into the tumor.